Table 2.
Demographic and clinical characteristics of both groups.
| Characteristics | ESWT Group | Cryo-US Group | p Value (95%;CI) |
|---|---|---|---|
| Patients, no. | 40 | 40 | |
|
| |||
| Age, mean±SD, (range), years | 49.7±9.9 (25–74) | 53.4±10.8 (32–75) | 0.114 (−8.31; 0.912) |
|
| |||
| Gender, no.(%) | |||
| Male | 29 (72.5) | 24 (60) | 0.344 (−0.08; 0.32) |
| Female | 11 (27.5) | 16 (40) | |
|
| |||
| Duration of symptoms, mean±SD, (range), months | 5.5±1.5 (4–8) | 6±1.5 (4–8) | 0.117 (−1.17; 0.17) |
|
| |||
| Side, no.(%) | |||
| Right | 29 (72.5) | 29 (72.5) | 0.802 (−0.19; 0.19) |
| Left | 11 (27.5) | 11 (27.5) | |
|
| |||
| Patients affected in their dominant arm, no. (%) | 31 (77.5) | 30 (75) | 1.000 (−0.16; 0.21) |
|
| |||
| VAS on resisted extension of the wrist, mean±SD, (range), cm | 6.5±1.5 (6–9) | 6.6±1.6 (6–10) | 0.774 (−0.79; 0.59) |
|
| |||
| Previous treatments, no (%) | |||
| NSAIDs | 23 (57.5) | 22 (55.0) | 1.000 (−0.18; 0.23) |
| Functional brace | 3 (7.5) | 6 (15.0) | 0.479 (−0.22; 0.07) |
| Rest | 14 (35.0) | 12 (30.0) | 0.811 (−0.15; 0.25) |
Abbreviations: ESWT, extracorporeal shockwave therapy; Cryo-US, cryoultrasound therapy; CI, confidence interval; no., number; SD, standard deviation; VAS, visual analogue scale.